NIKI
Niki BioSolutions, Inc. (NIKI) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Current ratio of 0.78 versus more liquid peers suggests tighter near-term working-capital headroom, which can constrain growth execution if demand or inventory needs rise.
Interest coverage of -5.5 versus profitable peers indicates earnings are not covering financing costs, increasing sensitivity to rate pressure and margin volatility.
Net debt is low at 0.01x EBITDA, but weaker liquidity than stronger balance-sheet peers still leaves NIKI more exposed to short-term funding stress.
Negative coverage alongside sub-1.0 liquidity can amplify downside if peers sustain better cash generation, making NIKI less resilient in a softer demand environment.
Opportunities
Net debt near zero versus leveraged peers provides balance-sheet flexibility, which can support working-capital funding and preserve optionality if demand improves.
Low debt-to-equity of 0.15 versus more levered competitors reduces refinancing risk, potentially allowing NIKI to defend margins better in a higher-rate backdrop.
If operating performance normalizes, the absence of meaningful leverage could let NIKI convert incremental earnings into faster equity value recovery than debt-heavy peers.
A lean capital structure can be advantageous versus peers when external conditions stabilize, because less cash is diverted to interest and principal servicing.
Overall Score
NIKI’s near-zero leverage is a relative strength, but weak liquidity and negative interest coverage versus stronger peers keep forward positioning only moderately favorable.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Niki BioSolutions, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
